PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16079895-6	2005	Thal/Dex administration resulted in a significant reduction of sRANKL/OPG ratio, and bone resorption.	Dextromethorphan	5-8	TNF receptor superfamily member 11b	Homo sapiens	70-73	
16079895-13	2005	These results suggest that the combination of intermediate dose of Thal/Dex is effective in patients with refractory/relapsed myeloma and improves abnormal bone remodeling through the reduction of sRANKL/OPG ratio.	Dextromethorphan	72-75	TNF receptor superfamily member 11b	Homo sapiens	204-207